Access Program Information
To provide access to ivosidenib monotherapy to patients with relapsed or refractory acute
myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation.
- Home
- /
- Access Program
- /
- Agios Pharmaceuticals, Inc. –...